切换至 "中华医学电子期刊资源库"

第五届中国出版政府奖音像电子网络出版物奖提名奖

中国科技核心期刊

中国科学引文数据库(CSCD)来源期刊

中华重症医学电子杂志 ›› 2024, Vol. 10 ›› Issue (01) : 85 -89. doi: 10.3877/cma.j.issn.2096-1537.2024.01.014

病例报告

TDM指导特重度烧伤脓毒症患者多黏菌素B的个体化治疗一例
刘霞1, 赵双平2,()   
  1. 1. 410008 长沙,中南大学湘雅医院重症医学科;413400 湖南桃江,湖南省益阳市桃江县人民医院重症医学科
    2. 410008 长沙,中南大学湘雅医院重症医学科
  • 收稿日期:2023-04-05 出版日期:2024-02-28
  • 通信作者: 赵双平

TDM guided the individualized treatment of polymyxin B in a patient with severe burn sepsis

Xia Liu1, Shuangping Zhao2,()   

  1. 1. Department of Critical Care Medicine, Xiangya Hospital, Central South University, Changsha 410008, China;Department of Critical Care Medicine, Taojiang County People's Hospital, Taojiang 413400, China
    2. Department of Critical Care Medicine, Xiangya Hospital, Central South University, Changsha 410008, China
  • Received:2023-04-05 Published:2024-02-28
  • Corresponding author: Shuangping Zhao
引用本文:

刘霞, 赵双平. TDM指导特重度烧伤脓毒症患者多黏菌素B的个体化治疗一例[J/OL]. 中华重症医学电子杂志, 2024, 10(01): 85-89.

Xia Liu, Shuangping Zhao. TDM guided the individualized treatment of polymyxin B in a patient with severe burn sepsis[J/OL]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2024, 10(01): 85-89.

1例特重度烧伤患者,烧伤面积约85%(深Ⅱ~Ⅲ度),烧伤后创面急性大量渗出、持续19 d行连续性肾脏替代治疗(CRRT),继发创面、肺部、血流及消化道的泛耐药鲍曼不动杆菌感染,合并多器官功能衰竭,予以积极处理创面,仍有反复感染,多次启动以多黏菌素B为基础的联合治疗方案,并通过治疗药物监测(TDM)在治疗期间多次监测多黏菌素B的药物浓度,合理调整给药剂量,在患者行左小腿截肢术后,体质量发生变化,药物浓度较前偏高,后通过剂量调整,最终使患者感染得到有效控制。

One patient with extremely severe burn, with an area of about 85% (deep second to third degree), received continuous renal replacement therapy (CRRT) for 19 days. This was prompted by a sudden and significant release of fluid from the burn wound, followed by an infection caused by pan-drug resistant Acinetobacter baumannii. The infection affected various parts of the body, including the wound, lungs, bloodstream, and digestive tract, leading to multiple organ failure. Despite active treatment of the wound, the patient experienced recurring infections and required multiple rounds of combined treatment involving polymyxin B. Through therapeutic drug monitoring (TDM), the drug concentration of polymyxin B was monitored many times throughout treatment, allowing for appropriate dosage adjustment. After the amputation of the left leg, there was a change in body mass and an increase in drug concentration. Finally, through the adjustment of the dosage, the patient's infection was well controled.

图1 1例特重度烧伤患者每日出入水量
图2 1例特重度烧伤患者每日最高体温曲线
图3 1例特重度烧伤患者感染指标变化趋势图
图4 1例特重度烧伤患者抗生素使用情况
1
Tsuji BT, Pogue JM, Zavascki AP, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP) [J]. Pharmacotherapy, 2019, 39(1): 10-39.
2
罗高兴, 詹日兴, 袁志强, 等. 浅谈烧伤感染的分类与诊断命名 [J]. 中华烧伤与创面修复杂志, 2023, 39(4): 301-304.
3
张梓晨, 陈伟, 郑舒芩, 等. 498例成人特重度烧伤患者的临床资料分析 [J]. 昆明医科大学学报, 2022, 43(10): 90-97.
4
Oczkowski S, Alshamsi F, Belley-Cote E, et al. Surviving Sepsis Campaign Guidelines 2021: highlights for the practicing clinician [J]. Pol Arch Intern Med, 2022, 132(7-8): 16290.
5
中国医药教育协会感染疾病专业委员会, 中华医学会呼吸病学分会, 中华医学会重症医学分会, 等. 中国多黏菌素类抗菌药物临床合理应用多学科专家共识 [J]. 中华结核和呼吸杂志, 2021, 44(4): 292-310.
6
Munster AM, Xiao GX, Guo Y, et al. Control of endotoxemia in burn patients by use of polymyxin B [J]. J Burn Care Rehabil, 1989, 10(4): 327-330.
7
Lyons JM, Davis C, Rieman MT, et al. Prophylactic intravenous immune globulin and polymixin B decrease the incidence of septic episodes and hospital length of stay in severely burned children [J]. J Burn Care Res, 2006, 27(6): 813-818.
8
Kang JS, Lee MH. Overview of therapeutic drug monitoring [J]. Korean J Intern Med, 2009, 24(1): 1-10.
9
Martin-Loeches I. Therapeutic drug monitoring (TDM) in real-time: a need for the present future [J]. Expert Rev Anti Infect Ther, 2022, 20(10): 1245-1247.
10
Liu X, Huang C, Bergen PJ, et al. Chinese consensus guidelines for therapeutic drug monitoring of polymyxin B, endorsed by the Infection and Chemotherapy Committee of the Shanghai Medical Association and the Therapeutic Drug Monitoring Committee of the Chinese Pharmacological Society [J]. Zhejiang Univ Sci B, 2023, 24(2): 130-142.
11
Malbrain MLNG, Van Regenmortel N, Saugel B, et al. Principles of fluid management and stewardship in septic shock: it is time to consider the four D's and the four phases of fluid therapy [J]. Ann Intensive Care, 2018, 8(1): 66.
12
Malbrain MLNG, Langer T, Annane D, et al. Intravenous fluid therapy in the perioperative and critical care setting: executive summary of the International Fluid Academy (IFA) [J]. Ann Intensive Care, 2020, 10(1): 64.
13
Jamal JA, Economou CJ, Lipman J, et al. Improving antibiotic dosing in special situations in the ICU: burns, renal replacement therapy and extracorporeal membrane oxygenation [J]. Curr Opin Crit Care, 2012, 18(5): 460-471.
14
Deng Y, Gu JY, Li X, et al. Does monitoring total and free polymyxin B1 plasma concentrations predict polymyxin B-induced nephrotoxicity? A retrospective study in critically ill patients [J]. Infect Dis Ther, 2022, 11(4): 1591-1608.
15
Sandri AM, Landersdorfer CB, Jovan J, et al. Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis [J]. J Antimicrob Chemother, 2013, 68(3): 674-677.
16
张雨昇, 罗雪梅, 成晓亮, 等. CRRT对重症感染患者多黏菌素B血药浓度, 疗效及安全性的影响 [J]. 中国医院药学杂志, 2021, 41(22): 2342-2347.
17
孙仁华, 刘景全. 重症患者连续性肾脏替代治疗时抗生素剂量调整 [J]. 现代实用医学, 2016, 28(8): 981-984.
18
Sader HS, Rhomberg PR, Farrell DJ, et al. Differences in potency and categorical agreement between colistin and polymyxin B when testing 15, 377 clinical strains collected worldwide [J]. Diagn Microbiol Infect Dis, 2015, 83(4): 379-381.
[1] 庄燕, 戴林峰, 张海东, 陈秋华, 聂清芳. 脓毒症患者早期生存影响因素及Cox 风险预测模型构建[J/OL]. 中华危重症医学杂志(电子版), 2024, 17(05): 372-378.
[2] 杨瑾, 刘雪克, 张媛媛, 金钧, 韦瑶. 肠道微生物来源石胆酸对脓毒症相关肝损伤的保护作用[J/OL]. 中华危重症医学杂志(电子版), 2024, 17(04): 265-274.
[3] 张霞, 张瑞, 郑志波, 张勤. 紫草素调控乳酸化修饰和线粒体功能改善脓毒症心肌病小鼠的预后[J/OL]. 中华危重症医学杂志(电子版), 2024, 17(04): 275-284.
[4] 张婧琦, 江洋, 孙佳璐, 唐兴喆, 赵宇飞, 崔颖, 李信响, 戴景月, 傅琳, 彭新桂. 基于肾周CT特征结合血清肌酐水平探讨脓毒症伴急性肾损伤的早期识别[J/OL]. 中华危重症医学杂志(电子版), 2024, 17(04): 285-292.
[5] 李振翮, 魏长青, 甄国栋, 李振富. 脓毒症并发急性呼吸窘迫综合征患者血清S1P、Wnt5a变化及其临床意义[J/OL]. 中华危重症医学杂志(电子版), 2024, 17(04): 293-300.
[6] 成人脓毒症患者β-内酰胺类抗生素延长输注专家共识编写组. 成人脓毒症患者β-内酰胺类抗生素延长输注专家共识[J/OL]. 中华重症医学电子杂志, 2024, 10(04): 313-324.
[7] 邱英鹏, 李欣雨, 邱海波, 刘松桥, 张凌, 于湘友, 秦秉玉, 蒲莹莹, 赵佳钰, 刘永军, 肖月, 杨毅. 连续性肾脏替代治疗质量控制指标体系的建立及验证[J/OL]. 中华重症医学电子杂志, 2024, 10(04): 351-357.
[8] 向阳, 史黎炜, 肖月, 邱海波, 杨毅, 刘松桥, 邱英鹏, 张莹. 连续性肾脏替代治疗在我国五地区重症医学科的效率分析[J/OL]. 中华重症医学电子杂志, 2024, 10(04): 358-363.
[9] 赵佳钰, 邱英鹏, 刘松桥, 杨毅, 张凌, 于湘友, 秦秉玉, 邱海波, 史黎炜, 刘克军, 蒲莹莹, 陈子扬, 赵羽西, 刘永军, 肖月. 连续性肾脏替代治疗在我国五地区重症医学科的应用现况[J/OL]. 中华重症医学电子杂志, 2024, 10(04): 364-374.
[10] 陈曦, 吴宗盛, 郑明珠, 邱海波. 胸腺萎缩在脓毒症免疫紊乱中的研究进展[J/OL]. 中华重症医学电子杂志, 2024, 10(04): 379-383.
[11] 杨翔, 郭兰骐, 谢剑锋, 邱海波. 转录组学在脓毒症诊疗中的临床研究进展[J/OL]. 中华重症医学电子杂志, 2024, 10(04): 384-388.
[12] 胡梓菡, 彭菲, 孙骎, 杨毅. 细胞外囊泡在脓毒症血管内皮损伤作用中的研究进展[J/OL]. 中华重症医学电子杂志, 2024, 10(03): 265-270.
[13] 刘娟丽, 马四清, 乌仁塔娜. 髓源性抑制细胞在脓毒症中的研究进展[J/OL]. 中华重症医学电子杂志, 2024, 10(03): 271-278.
[14] 陈惠英, 邱敏珊, 邵汉权. 脓毒症诱发肠黏膜屏障功能损伤的风险因素模型构建与应用效果[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 448-452.
[15] 傅新露, 李之岳, 卢丹. 妊娠合并结肠癌穿孔致脓毒症休克一例并文献复习[J/OL]. 中华产科急救电子杂志, 2024, 13(04): 227-231.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?